内分泌治疗联合白蛋白结合型紫杉醇在中晚期前列腺癌患者中的应用

发布时间：2018-05-03 16:28

本文选题：前列腺肿瘤 + 内分泌干扰物　；参考：《肿瘤》2017年07期

【摘要】：目的 :观察比卡鲁胺、戈舍瑞林持续内分泌治疗联合注射用白蛋白结合型紫杉醇、泼尼松在中晚期前列腺癌患者中的临床疗效。方法:将100例确诊为中晚期前列腺癌的患者随机分为对照组和观察组各50例。对照组患者采用比卡鲁胺片联合醋酸戈舍瑞林缓释植入剂治疗,观察组在对照组用药基础上加用注射用白蛋白结合型紫杉醇和泼尼松治疗。治疗3个周期后,比较2组患者的临床疗效和不良反应。结果:观察组患者的完全缓解率(22.0%)和部分缓解率(60%)高于对照组(8%和40%,P值均0.05);观察组患者的中位生存期和中位无进展生存期(51个月和54个月)均长于对照组(33个月和30个月,P值均0.05)。观察组患者的临床症状(疼痛、血清前列腺特异性抗原、前列腺体积和最大尿流率)明显改善。2组患者不良反应间的差异无统计学意义(P0.05)。结论:内分泌药物联合注射用白蛋白结合型紫杉醇和泼尼松在中晚期前列腺癌患者中的疗效较好。
[Abstract]:Objective: to observe the clinical effect of continuous endocrine therapy with Bisalamin and goserelin combined with albumin bound paclitaxel and prednisone in patients with advanced prostate cancer. Methods: 100 patients with advanced prostate cancer were randomly divided into control group (n = 50) and observation group (n = 50). The patients in the control group were treated with Bisalamine tablets combined with sustained release implants of goserelin acetate, and those in the observation group were treated with Albumin combined with paclitaxel and prednisone for injection on the basis of the drug used in the control group. After 3 cycles of treatment, the clinical efficacy and adverse reactions of the two groups were compared. Results: the complete remission rate (22.0%) and partial remission rate (60%) in the observation group were higher than those in the control group (8% and 40%), and the median survival time and median progression-free survival time (51 months and 54 months) in the observation group were longer than those in the control group (33 months). P value was 0.05 and 0.05% respectively in 30 months and 30 months. The clinical symptoms (pain, serum prostate specific antigen, prostate volume and maximal urine flow rate) in the observation group improved significantly the difference of adverse reactions between the two groups (P 0.05). Conclusion: endocrine drugs combined with albumin-bound paclitaxel and prednisone are effective in patients with advanced prostate cancer.
【作者单位】：西宁海湖医院肿瘤内科;
【分类号】：R737.25

【相似文献】